MALDI-MS-based Validation of a 110 SNV Pharmacogenomic Panel for Pain Management Providers
Grace Williams (1), Leanne Cook (1), Gregory Tsongalis(1), and Robert Nerenz (1) Dartmouth-Hitchcock Medical Center
Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704
Grace Williams (Presenter) Dartmouth-Hitchcock Medical Center
Presenter Bio: Grace Williams is a 2nd year chemistry fellow at Dartmouth-Hitchcock Medical Center in Lebanon, NH. She received her PhD in pharmacology in 2017 from the Medical University of South Carolina with a phosphoproteomics-centered dissertation project. Upon starting chemistry fellowship she made the leap to molecular biology using MALDI-TOF MS for pharmacogenomic analysis of germline DNA. When not working, Grace enjoys going to see live music and purchasing coats for use in the cold NH winters!
Relevant Financial Disclosures
(within past 24 months)
No relevant financial relationship(s) to disclose.
Abstract
Recent combinations of genetic biochemical tools and MS methods have allowed for sensitive and rapid processing of patient samples for pharmacogenomic profiling in the clinic. The goal of this study was to validate the analytic performance of the Agena MassARRAY MALDI-TOF instrument; iPLEX® PGx 74 panel, and a custom designed PGx panel in a clinical laboratory setting. We assessed the analytic performance of the MassARRAY for accuracy, intra- and inter-operator precision, DNA quality, and dilution effects. The Agena MassARRAY PGx74 and custom panel provide an accurate and targeted approach to SNV detection in pain management patients.
= Discovery stage. (17.55%, 2019 US)
= Translation stage. (42.72%, 2019 US)
= Clinically available. (39.74%, 2019 US)
